Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Core Insights - Merck & Co. has reported Q3 2025 results that exceeded market expectations in terms of revenue and earnings [1] Financial Performance - The company achieved better-than-expected top-line results, indicating strong operational performance [1] Market Position - As 2026 approaches, Merck & Co. is in a unique position within the pharmaceutical industry, suggesting potential for future growth and investment opportunities [1]